cladribine has been researched along with Graft-Versus-Host Disease in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 10 (55.56) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 3 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, SZ; Han, MZ; He, Y; Jiang, EL; Shi, YY; Zhang, GX; Zhang, RL | 1 |
| DU, JW; He, YZ; Huang, YX; Li, KX; Li, YH; Pan, WY; Song, CY; Tu, SF; Wu, HY; Zheng, YL | 1 |
| Huang, L; Huang, W; Jin, J; Li, L; Li, M; Li, Y; Mao, X; Meng, F; Peng, Y; Tong, X; Xu, B; Zhang, D | 1 |
| Bosdure, E; Donadieu, J; Galambrun, C; Garaix, F; Mace, L; Petit, P; Picard, C; Poullin, P; Stremler, N; Ughetto, F | 1 |
| Mick, AB | 1 |
| Allred, JB; Ansell, SM; Dispenzieri, A; Elliott, MA; Gastineau, DA; Gertz, MA; Geyer, SM; Hogan, WJ; Inwards, DJ; Lacy, MQ; Larsen, JT; Litzow, MR; Micallef, IN; Porrata, LF; Roy, V; Tefferi, A; Tun, HW; Wu, W | 1 |
| Kami, M; Kanda, Y; Makimoto, A; Mineishi, S; Nakai, K; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H | 1 |
| Arima, F; Heike, Y; Kami, M; Kanda, Y; Kim, SW; Mineishi, S; Nakai, K; Saito, T; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H | 1 |
| Hamaki, T; Heike, Y; Hori, A; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Kusumi, E; Masuo, S; Miyakoshi, S; Mori, S; Morinaga, S; Murashige, N; Muto, Y; Takaue, Y; Taniguchi, S; Tanosaki, R; Ueyama, J; Yuji, K | 1 |
| Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Takaue, Y; Taniguchi, S; Tanosaki, R; Tobinai, K | 1 |
| Arora, M; Barker, JN; Blazar, BR; Burns, LJ; DeFor, T; Douek, D; MacMillan, ML; Markova, M; Miller, JS; Repka, T; Tan, Y; Wagner, JE; Weisdorf, DJ | 1 |
| Hamaki, T; Hori, A; Kami, M; Kanda, Y; Katayama, Y; Kishi, Y; Kobayashi, K; Mori, S; Murashige, N; Onishi, Y; Tajima, K; Takaue, Y; Tanosaki, R | 1 |
| Alberto, P; Betticher, DC; Diebold-Berger, S; Extermann, M; Helg, C; Reymond, JM; Roux, E; Tiercy, JM; Zubler, R; Zulian, GB | 1 |
| Betticher, DC; Gratwohl, A; Pless, M; Speck, B; Tichelli, A | 1 |
| Anderlini, P; Andersson, BS; Andreeff, M; Braunschweig, I; Bruton, J; Champlin, R; Claxton, D; Cohen, A; Davis, M; Donato, M; Gajewski, J; Giralt, S; Ippolitti, C; Khouri, I; Kornblau, S; Molldrem, J; Przepiorka, D; Thall, PF; Ueno, NT; Wang, X | 1 |
| Kanai, S; Kanda, Y; Makimoto, A; Mineishi, S; Miyawaki, S; Nakai, K; Niiya, H; Ohnishi, M; Ohnishi, T; Saito, A; Saito, T; Suenaga, K; Takaue, Y; Takeuchi, T; Tanosaki, R; Tobinai, K | 1 |
| Baker, KS; Nagarajan, R; Neglia, J; Ramsay, N | 1 |
| Kami, M; Kanai, S; Kanda, Y; Kato, K; Kawano, Y; Makimoto, A; Matsubara, H; Mineishi, S; Nakai, K; Ogasawara, T; Ohnishi, T; Saito, T; Shoji, N; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H | 1 |
1 review(s) available for cladribine and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Successful treatment of refractory Langerhans cell histiocytosis with unrelated cord blood transplantation.
Topics: Bone Marrow; Cladribine; Combined Modality Therapy; Cyclosporine; Cytarabine; Doxorubicin; Drug Therapy, Combination; Etoposide; Female; Fetal Blood; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histiocytosis, Langerhans-Cell; Humans; Infant, Newborn; Mercaptopurine; Methotrexate; Methylprednisolone; Prednisone; Remission Induction; Transplantation, Homologous; Vinblastine | 2001 |
6 trial(s) available for cladribine and Graft-Versus-Host Disease
| Article | Year |
|---|---|
A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome | 2013 |
Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cladribine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immune System; Immunosuppression Therapy; Infections; Kinetics; Lymphocyte Count; Lymphocyte Subsets; Male; Middle Aged; Regeneration; Transplantation Conditioning; Transplantation, Homologous | 2003 |
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Cladribine; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Cladribine; Combined Modality Therapy; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Prospective Studies; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation.
Topics: Acute Disease; Adenosine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cladribine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2001 |
Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Staphylococcal Infections; Survival Analysis; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome | 2002 |
11 other study(ies) available for cladribine and Graft-Versus-Host Disease
| Article | Year |
|---|---|
[Clinical outcomes of 31 patients with acute leukemia receiveing modified conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation].
Topics: Cladribine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Transplantation Conditioning; Transplantation, Autologous | 2021 |
[Efficacy and Safety of Cladribine-based Intensified Conditioning Regimen in Hematopoietic Stem Cell Transplantation in Patients with High-Risk Acute Myeloid Leukemia].
Topics: Busulfan; Cladribine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Transplantation Conditioning | 2022 |
Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Chronic Disease; Cladribine; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Retrospective Studies | 2023 |
Cladribine-related immunosuppression may have fostered graft-versus-host disease after lung transplant for pulmonary Langerhans cell histiocytosis.
Topics: Child, Preschool; Cladribine; Fatal Outcome; Female; Graft vs Host Disease; Histiocytosis, Langerhans-Cell; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Lung Diseases; Lung Transplantation | 2019 |
Clinical Pearls.
Topics: Adolescent; Adult; Cladribine; Contact Lenses; Diplopia; Exophthalmos; Eye Diseases; Eyelid Diseases; Goldenhar Syndrome; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Mastocytosis; Middle Aged | 2016 |
Impact of graft-versus-host disease in reduced-intensity stem cell transplantation (RIST) for patients with haematological malignancies.
Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Chronic Disease; Cladribine; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Middle Aged; Proportional Hazards Models; Recurrence; Stem Cell Transplantation; Survival Rate; Thyroglobulin; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2003 |
Feasibility of reduced intensity hematopoietic stem cell transplantation from an HLA-matched unrelated donor.
Topics: Adult; Aged; Antilymphocyte Serum; Bone Marrow Transplantation; Cladribine; Feasibility Studies; Female; Graft vs Host Disease; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Histocompatibility; Histocompatibility Testing; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation Immunology; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2004 |
Characterization of acute graft-versus-host disease following reduced-intensity stem-cell transplantation from an HLA-identical related donor.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Disease-Free Survival; Family; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Middle Aged; Retrospective Studies; Time Factors; Transplantation, Homologous; Vidarabine | 2008 |
Transfusion-associated graft-versus-host disease in a patient treated with Cladribine (2-chlorodeoxyadenosine): demonstration of exogenous DNA in various tissue extracts by PCR analysis.
Topics: Aged; Cladribine; DNA; DNA, Satellite; Female; Graft vs Host Disease; Histocompatibility Antigens Class I; HLA-DR Antigens; Humans; Immunocompromised Host; Platelet Transfusion; Polymerase Chain Reaction; Transplantation Chimera | 1995 |
2-Chlorodeoxyadenosine as treatment of severe acute graft-versus-host disease.
Topics: Acute Disease; Adult; Anemia, Aplastic; Bone Marrow Transplantation; Cladribine; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male | 1994 |
Successful application of nonmyeloablative transplantation for paroxysmal nocturnal hemoglobinuria.
Topics: Antilymphocyte Serum; Busulfan; Cladribine; Cyclosporine; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hemoglobinuria, Paroxysmal; Histocompatibility; Humans; Immunosuppressive Agents; Male; Middle Aged; Transplantation Conditioning; Transplantation, Homologous | 2001 |